Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug delivery of oligonucleotides by peptides.
Lochmann D, Jauk E, Zimmer A. Lochmann D, et al. Eur J Pharm Biopharm. 2004 Sep;58(2):237-51. doi: 10.1016/j.ejpb.2004.03.031. Eur J Pharm Biopharm. 2004. PMID: 15296952 Review.
A practical note on the use of cytotoxicity assays.
Weyermann J, Lochmann D, Zimmer A. Weyermann J, et al. Among authors: lochmann d. Int J Pharm. 2005 Jan 20;288(2):369-76. doi: 10.1016/j.ijpharm.2004.09.018. Epub 2004 Dec 2. Int J Pharm. 2005. PMID: 15620877
Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Lochmann D, et al. Eur J Pharm Biopharm. 2005 Apr;59(3):419-29. doi: 10.1016/j.ejpb.2004.04.001. Eur J Pharm Biopharm. 2005. PMID: 15760722
In this paper, a ternary system of albumin-protamine-oligonucleotide nanoparticles (AlPrO-NP) recently developed by Vogel et al. [V. Vogel, D. Lochmann, J. Weyermann, G. Mayer, C. Tziatzios, J.A. van den Broek, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, …
In this paper, a ternary system of albumin-protamine-oligonucleotide nanoparticles (AlPrO-NP) recently developed by Vogel et al. [V. Vogel, …
Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
Weyermann J, Lochmann D, Georgens C, Zimmer A. Weyermann J, et al. Among authors: lochmann d. Eur J Pharm Biopharm. 2005 Apr;59(3):431-8. doi: 10.1016/j.ejpb.2004.07.014. Eur J Pharm Biopharm. 2005. PMID: 15760723
The purpose of this work is to characterise a new drug delivery system developed by [V. Vogel, D.Lochmann, J. Weyermann, G. Mayer, C. Tziatios, J.A. van der Brock, W. Haase, D. Wouters, U.S. Schubert, J. Kreuter, A. Zimmer, D. Schubert, Oligonucleotide …
The purpose of this work is to characterise a new drug delivery system developed by [V. Vogel, D.Lochmann, J. Weyermann, G. Ma …
Advanced stable lipid-based formulations for a patient-centric product design.
Becker K, Saurugger EM, Kienberger D, Lopes D, Haack D, Köberle M, Stehr M, Lochmann D, Zimmer A, Salar-Behzadi S. Becker K, et al. Among authors: lochmann d. Int J Pharm. 2016 Jan 30;497(1-2):136-49. doi: 10.1016/j.ijpharm.2015.11.039. Epub 2015 Nov 24. Int J Pharm. 2016. PMID: 26621689
35 results